PLUS1
22.00
-0.665 (-2.93%)
-0.665 (-2.93%)
Upgrade to Real-Time
Afterhours
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Adverum Biotechnologies Inc | ADVM | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 2.40 | 11.82% | 22.665 | 20.16 | 22.69 | 20.67 | 20.27 | 17:15:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 20.48 | 22.83 | 2.35 | 10.29% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 9,454 | 1,211,020 | $ 21.82 | $ 26,420,502 | 1,493,788 | 4.96 - 23.7899 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:00:12 | 4 | $ 22.00 | USD |
Adverum Biotechnologies Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 1.81B | 79.97M | 75.56M | $ 250.00k | $ - | -1.01 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 13.00 | 5.50% |
Adverum Biotechnologies News
| Date | Time | Source | News Article |
|---|---|---|---|
| 6/04/2020 | 16:05 | GlobeNewswire Inc. | Adverum Biotechnologies to Participate in Goldman Sachs 41st.. |
| 5/28/2020 | 16:17 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 5/28/2020 | 16:01 | GlobeNewswire Inc. | Adverum Biotechnologies Announces New INFINITY Phase 2 Trial.. |
| 5/22/2020 | 18:56 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 5/21/2020 | 16:05 | GlobeNewswire Inc. | Adverum Biotechnologies to Host a Conference Call and.. |
| 5/20/2020 | 19:35 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 5/20/2020 | 19:34 | Edgar (US Regulatory) | Amended Statement of Changes in Beneficial Ownership (4/a) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ADVM Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 19.46 | 22.69 | 16.55 | 20.81 | 953,029 | 3.21 | 16.47% |
| 1 Month | 20.05 | 22.69 | 16.55 | 19.59 | 983,729 | 2.62 | 13.04% |
| 3 Months | 8.02 | 23.7899 | 7.43 | 14.55 | 1,357,585 | 14.65 | 182.61% |
| 6 Months | 11.31 | 23.7899 | 7.36 | 13.21 | 1,376,288 | 11.36 | 100.4% |
| 1 Year | 11.06 | 23.7899 | 4.96 | 11.09 | 1,430,047 | 11.61 | 104.93% |
| 3 Years | 2.70 | 23.7899 | 2.40 | 8.50 | 894,745 | 19.97 | 739.44% |
| 5 Years | 38.7548 | 41.60 | 2.40 | 8.53 | 676,419 | -16.09 | -41.52% |
Adverum Biotechnologies Description
| Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company. The company is committed to discovering and developing novel medicines that can offer potentially life-changing therapeutic benefit to patients living with rare diseases or diseases of the eye, who currently have limited or burdensome treatment options. Its services are focused on advancing three lead gene therapy programs to address unmet needs in wet age-related macular degeneration and in rare diseases alpha-1 antitrypsin deficiency and hereditary angioedema. Its leading programs include ADVM-022, ADVM-043 and ADVM-053. |
